Document is current
Any future updates will be listed below
-
Authors
Tshiongo, Japhet Kabalu
Khote, Flory Luzolo
Kabena, Melissa
Mavoko, Hypolite Muhindo
Kalonji-Mukendi, Thierry
Luzolo, Landrine
Schallig, Henk D. F. H.
Kayentao, Kassoum
Mens, Petra F.
Lutumba, Pascal
Tinto, Halidou
Maketa, Vivi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04783051 at ClinicalTrials.govDocuments that mention this clinical trial
Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC
https://doi.org/10.1186/s12936-025-05260-6
-
Funding
Funding for this research was provided by:
This project is a part of the EDCTP2 program supported by the European Union (TMA2019CDF-2699-ULTRAPYRAPREG)
Novartis
- License Information
-
More Information
Article History
Received: 8 October 2024
Accepted: 15 January 2025
First Online: 21 February 2025
Declarations
:
: The study was reviewed and approved by the National Ethics Committee of the DRC (approval reference: 169/CNES/BN/PMMF/2019 of March 13, 2020) and the Congolese Pharmaceutical Regulatory Authority (ACOREP) (approval reference: MS1253/P/DKK/01096/2020 of October 9, 2020).
: Not applicable.
: The authors declare that they have no competing interests.
